Cardiovascular Complications of Carfilzomib

Evaluation and Management of Cardio Toxicity in Oncologic Patients

NCT02818517 ·Status: RECRUITING

Innovative Biomarkers of Cardiovascular Complications Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Treatments: a Single-center Cohort Study

NCT07174141 ·Status: RECRUITING

JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors

NCT04294771 ·Status: UNKNOWN

Prevention and Pharmacological Management of Cardiac Adverse Drug Reactions Induced by Drugs Used in Oncology.

NCT03678337 ·Status: UNKNOWN

Is Sacubitril-valsartan Superior to Dapagliflozin in Improving Myocardial Function Performance

NCT06090487 ·Status: COMPLETED ·Phase: NA

LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.

NCT07202897 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Evaluation of Reporting of Cardio-vascular Adverse Events With Antineoplastic and Immunomodulating Agents (EROCA)

NCT03530215 ·Status: COMPLETED

BMI-Driven Tolerability and Efficacy of Entresto in Heart Failure Patients

NCT06439069 ·Status: RECRUITING

Cardiometabolic Effects of Dapagliflozin in Heart Failure With Reduced or Mildly Reduced Ejection Fraction

NCT05420285 ·Status: UNKNOWN ·Phase: PHASE2

Assessment of Myocardial Injury in Patients Treated With Immune Checkpoint Inhibitors

NCT05349058 ·Status: UNKNOWN

Forxiga HF General Drug Use-Results Study

NCT04865406 ·Status: COMPLETED

Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.

NCT05879276 ·Status: RECRUITING ·Phase: PHASE3

Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure

NCT00259038 ·Status: COMPLETED ·Phase: PHASE2

Carvedilol Vascular Efficacy Trial

NCT01484327 ·Status: COMPLETED

A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients

NCT00655538 ·Status: COMPLETED ·Phase: PHASE2

Monitoring Drug-induced Myocarditis (CardiTOX)

NCT03855982 ·Status: COMPLETED

Assessment of Global Longitudinal Strain for the Prediction of Anthracycline Induced Cardiotoxicity

NCT02875171 ·Status: COMPLETED

Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse Reactions

NCT03387540 ·Status: COMPLETED

Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure

NCT05236673 ·Status: COMPLETED

Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy

NCT05795400 ·Status: COMPLETED ·Phase: NA

Cardioprotection on Chemotherapy-Induced Cardiotoxicity

NCT06853951 ·Status: RECRUITING ·Phase: PHASE3

Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy

NCT05953831 ·Status: WITHDRAWN ·Phase: PHASE2

Risk Analysis of Cardiotoxic Medication Use Due to Sodium Arsenite Chloride Injection

NCT06060132 ·Status: UNKNOWN

Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698

NCT03044353 ·Status: TERMINATED ·Phase: PHASE2

A Morbidity-Mortality and Remodeling Study With Valsartan

NCT00133328 ·Status: UNKNOWN ·Phase: PHASE4